Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.
It didn’t take long for analysts to turn Pfizer's Q3 earnings conversation back to their favorite topic: M&A.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
If you thought Merck KGaA would press pause on selling its consumer health unit until Pfizer’s was off the market, think again.
Novartis' $3.9B deal for Advanced Accelerator Applications comes with a blockbuster-to-be, Lutathera, that could follow in Sandostatin's footsteps.
Shire shares have taken a beating this year, but they got a boost Friday from third-quarter earnings results investors viewed favorably.
GSK and Reckitt Benckiser have already declared interest in Pfizer’s consumer health unit. But they likely won’t be alone when bidding kicks off.
GlaxoSmithKline said it's looking hard at Pfizer’s OTC unit—but that was bad news to analysts worried about the fate of the company’s dividend.
Eli Lilly is looking at strategic options for animal health business Elanco that could include an IPO, merger, sale, or to keep the business.
When the year began, the prospect of U.S. tax reform had pharma companies salivating for some M&A action. But so far, that hasn't happened.
Obesity drugmaker Orexigen may be game for a sale. The question is, is anyone game for a buy?